Navigation Links
Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Council's Chairman of the Board
Date:11/2/2012

WASHINGTON, Nov. 2, 2012 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today announced that John Gargiulo, President & CEO, Daiichi Sankyo, Inc., has been elected Chairman of its Board of Directors for 2012-13. Mr. Gargiulo has served on NPC's Board since 2007, most recently as Vice Chair.

(Photo: http://photos.prnewswire.com/prnh/20121102/DC05271)

"For many years, John has been committed to fostering NPC's growth as a leading health care policy research organization," said NPC President Dan Leonard. "We're looking forward to his leadership as chairman.  He brings a strong track record of accomplishment from Daiichi Sankyo and a keen understanding of the issues facing our industry and actionable ideas for change."

"Now more than ever, we need to demonstrate that pharmaceuticals not only successfully treat and cure disease, but that they can help manage the costs of health care over time.  By managing chronic and preventable diseases with medicines that have proven to work, we can reduce hospitalizations, and most of all, help people lead longer and healthier lives," said Mr. Gargiulo. "As chairman, I'm looking forward to leading NPC as it continues to move forward on issues related to balancing the needs of patients with the population, the value of pharmaceuticals, and the use of real-world evidence."

Mr. Gargiulo has more than 25 years of pharmaceutical industry experience. He has been instrumental in building and shaping the company's U.S. commercial operations, particularly its cardiovascular business, since its inception in 1996. He has touched nearly every aspect of business operations including Marketing, Managed Markets and New Product Planning. In the U.S. Daiichi Sankyo markets therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome and metastatic melanoma.

The NPC Board also elected Jeff Huth
'/>"/>

SOURCE National Pharmaceutical Council
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il piĆ¹ ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
2. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
3. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
4. Varian Medical Systems Selected by Leading Russian Development Foundations to Take Part in High-Profile Supplier Event
5. DebMed Selected By Three Leading Healthcare Group Purchasing Organizations To Demonstrate Innovative Patient Safety Solution
6. Mylan Selected as a Leading ARV Supplier to Indias National AIDS Control Organization
7. NIH Director Francis S. Collins, M.D., Ph.D. Selected as 2012 Pro Bono Humanum Honoree by Prix Galien USA
8. Pharmaceutical Industry Veteran Al Altomari Elected To Insmeds Board Of Directors
9. Catherine Sohn Elected To Jazz Pharmaceuticals Board Of Directors
10. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
11. Nature Made Selected As "Top Recommended Health Product" By U.S. News & World Report And Pharmacy Times
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Novavax, Inc. (Nasdaq: NVAX ), a clinical-stage vaccine ... Novavax, will be presenting at the ROTH 23rd Annual OC ... local time at The Ritz Carlton, Laguna Niguel, CA.  A ... via the Company website at www.novavax.com under Investors/Events, ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... the extracellular matrix for the endocrinology, ... financial results for the fourth quarter and year ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) "I am energized and ...
Cached Medicine Technology:Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 6
(Date:4/18/2014)... online in The Gerontologist reports ... associated with a decrease in anxiety about death and ... over their lives. In particular, listening to gospel music ... and an increase in sense of control. , These ... men, and individuals of both low- and high-socioeconomic status. ...
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2
... ROCKVILLE, Md., March 5 Americans and nonprofit organizations ... of these circumstances, The Larry King Cardiac Foundation (LKCF), ... for individuals with no health insurance, has announced that ... 2009.In lieu of its annual black tie gala held ...
... happens may lead to ways around it, researchers say, ... standard treatment for brain cancer, may boost the aggressiveness ... a new study suggests. , The research team, from ... identified cells in brain tumors called gliomas that have ...
... response to a recent report by the National Council ... U.S. population is exposed to seven times more radiation ... Americans to consider the proven benefits of such imaging. ... technologists support the use of diagnostic imaging when deemed ...
... WASHINGTON, March 5 Stephen J. Ubl, president and CEO ... the Medical Device Safety Act to be introduced today in Congress. If ... , Chill innovation and ... Dramatically alter the regulatory environment for certain medical devices, ...
... March 5 Stephen J. Ubl, president ... released the following statement today regarding the re-introduction of ... not in any way improve patient safety. It will, ... a chilling effect on medical innovation, create more lawsuits ...
... Dialysis Corporation of America (Nasdaq: DCAI ) announced its financial ... , , ... dialysis center acquired December 31, 2008. , ... $23.7 million compared to $20.0 million for the same period last year, ...
Cached Medicine News:Health News:The Larry King Cardiac Foundation Brings its Annual Gala to Homes Across the Nation 2Health News:The Larry King Cardiac Foundation Brings its Annual Gala to Homes Across the Nation 3Health News:Brain Tumor Drug May Help Spur Cancer's Return 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 3Health News:Medical imaging benefits far outweigh radiation risks 2Health News:AdvaMed Response to the Medical Device Safety Act 2Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 2Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 3Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 4Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 5Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 6Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 7Health News:Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results 8
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Bipolar forceps...
... the pathologist to visualize the presence of Human ... a choice of sample types: tissue, monolayer-based preparations, ... proprietary probe formulations. The Family 16 probe cocktail ... 31, 33, 35, 39, 51, 52, 56, 58, ...
... Common primary human fungal pathogens ... spp., opportunistic fungal pathogens, including ... cerevisiae, Acremonium, Coccidioides immitis, Histoplasma ... and Pneumocystis carinii. The (1-3)--D-glucan ...
Medicine Products: